CDC study shows effectiveness of RSV immunization for infants

New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).

Read the original news at Centers for Disease Control and Prevention (CDC)